Teva Pharmaceutical Industries Ltd. TEVA today
announced that it has withdrawn its cash and stock proposal to acquire
all of the outstanding ordinary shares of Mylan N.V. MYL and
Teva does not intend to continue to pursue a transaction with Mylan at
this time. Teva's decision to terminate the proposal to acquire Mylan
follows today's announcement that Teva has entered into a definitive
agreement with Allergan to acquire Allergan Generics.
"In light of our strategic acquisition of Allergan Generics, which will
transform the industry, our Board and management team has decided that
withdrawing the proposal to acquire Mylan is in the best interests of
Teva stockholders," said Erez Vigodman, President and CEO of Teva.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in